GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Walvax Biotechnology Co Ltd (SZSE:300142) » Definitions » Debt-to-Equity

Walvax Biotechnology Co (SZSE:300142) Debt-to-Equity : 0.05 (As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Walvax Biotechnology Co Debt-to-Equity?

Walvax Biotechnology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ¥47 Mil. Walvax Biotechnology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ¥445 Mil. Walvax Biotechnology Co's Total Stockholders Equity for the quarter that ended in Dec. 2024 was ¥9,430 Mil. Walvax Biotechnology Co's debt to equity for the quarter that ended in Dec. 2024 was 0.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Walvax Biotechnology Co's Debt-to-Equity or its related term are showing as below:

SZSE:300142' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01   Med: 0.05   Max: 0.86
Current: 0.05

During the past 13 years, the highest Debt-to-Equity Ratio of Walvax Biotechnology Co was 0.86. The lowest was 0.01. And the median was 0.05.

SZSE:300142's Debt-to-Equity is ranked better than
82.23% of 816 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs SZSE:300142: 0.05

Walvax Biotechnology Co Debt-to-Equity Historical Data

The historical data trend for Walvax Biotechnology Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Walvax Biotechnology Co Debt-to-Equity Chart

Walvax Biotechnology Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.04 0.05 0.09 0.05

Walvax Biotechnology Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.09 0.08 0.08 0.05

Competitive Comparison of Walvax Biotechnology Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Walvax Biotechnology Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Walvax Biotechnology Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Walvax Biotechnology Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Walvax Biotechnology Co's Debt-to-Equity falls into.


;
;

Walvax Biotechnology Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Walvax Biotechnology Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Walvax Biotechnology Co's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Walvax Biotechnology Co  (SZSE:300142) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Walvax Biotechnology Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Walvax Biotechnology Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Walvax Biotechnology Co Business Description

Traded in Other Exchanges
N/A
Address
Kexin Road, No. 395, High-tech Zone, Yunnan Province, Kunming, CHN, 650101
Walvax Biotechnology Co Ltd is engaged in research and development, production and sales of vaccine products.
Executives
Wu Yun Yan Executives
Zhao Jin Long Executives
Yao Wei Executives
Zhou Hua Executives
Shi Jing Executives
Jiang Run Sheng Directors, executives
Gong Sun Qing Executives
Executives
Yuan Lin Executives
Fang Guo Liang Executives
Li Yun Chun Director
Huang Zhen Director
Zhang Li Secretary Dong
Yang Hong Wei Supervisors
Xu Ke Ren Executives

Walvax Biotechnology Co Headlines

No Headlines